Skip to main content

Advertisement

SpringerLink
Log in

Clinical Pharmacology of Itraconazole in Children and Adolescents

  • Pediatric Fungal Infections (T Lehrnbecher, Section Editor)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Invasive fungal infections are recognized as life-threatening complications primarily in immunocompromised patients, including children with primary immunodeficiencies and hematological malignancies. The antifungal triazoles have become extremely useful components of the antifungal armamentarium. They are well tolerated and possess a broad spectrum of activity. Itraconazole was discovered in 1984 and became available for clinical use in 1990. Itraconazole is a broad spectrum, triazole antifungal agent, and class II drug molecule with low solubility and high permeability and several indications in adults. This article provides a brief overview of the pharmacology of itraconazole with focus on the available data in immunocompromised children and adolescents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37:310–44.

    Article  CAS  PubMed  Google Scholar 

  2. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343–500.

    CAS  PubMed  Google Scholar 

  3. Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin Investig Drugs. 2000;9:593–605.

    Article  CAS  PubMed  Google Scholar 

  4. Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011;71:6764–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Rippon JW. A new era in antimycotic agents. Arch Dermatol. 1986;122:399–402.

    Article  CAS  PubMed  Google Scholar 

  6. Miranda KC, de Araujo CR, Costa CR, et al. Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents. 2007;29:281–4.

    Article  CAS  PubMed  Google Scholar 

  7. Trilles L, Fernandez-Torres B, Lazera Mdos S, et al. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol. 2004;42:4815–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995;39:1–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002;2:550–63. This is a very interesting review analyzing and reporting current therapeutic strategies to overcome antifungal resistance.

    Article  PubMed  Google Scholar 

  10. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:3–13.

    Article  Google Scholar 

  11. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994;18:240–2.

    Article  CAS  PubMed  Google Scholar 

  12. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309–16.

    Article  CAS  PubMed  Google Scholar 

  13. Kontoyiannis DP, Reddy BT, Hanna H, et al. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 2002;23:542–5.

    Article  PubMed  Google Scholar 

  14. Saag MS, Fessel WJ, Kaufman CA, et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retrovir. 1999;15:1413–7.

    Article  CAS  PubMed  Google Scholar 

  15. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010;6:e1000848.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123–9. An interesting study assessing the respiratory fungal load in bronchoalveolar lavage (BAL) and sputum specimens for Aspergillus DNA by using an ultrasensitive real-time polymerase chain reaction (PCR) assay.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219.

    Article  PubMed Central  PubMed  Google Scholar 

  18. van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg Infect Dis. 2011;17:1846–54.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole resistant aspergillosis. N Engl J Med. 2007;356:1481–3.

    Article  CAS  PubMed  Google Scholar 

  20. Burgess DS, Hastings RW. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis. 2000;38:87–93.

    Article  CAS  PubMed  Google Scholar 

  21. Burgess DS, Hastings RW, Summers KK, et al. Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn Microbiol Infect Dis. 2000;36:13–8.

    Article  CAS  PubMed  Google Scholar 

  22. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother. 1998;42:3018–21.

    PubMed Central  CAS  PubMed  Google Scholar 

  23. Denning DW, Radford SA, Oakley KL, et al. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 1997;40:401–14.

    Article  CAS  PubMed  Google Scholar 

  24. Berenguer J, Ali NM, Allende MC, et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother. 1994;38:1303–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61:27–37.

    Article  PubMed  Google Scholar 

  26. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42:443–51. Epidemiologic data concerning invasive fungal infections in neutropenic patients with haematological malignancies during antifungal prophylaxis with itraconazole.

    Article  CAS  PubMed  Google Scholar 

  27. Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother. 2007;51:2668–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Groll AH, Kolve H, Walsh TJ. Azoles. In: Yu VL, Edwards G, Mckinnon PS, et al., editors. Antimicrobial chemotherapy and vaccines, vol. 2. 2nd ed. Pittsburgh: ESun Technologies; 2005. p. 609–36.

    Google Scholar 

  29. Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother. 1995;36:657–63.

    Article  CAS  PubMed  Google Scholar 

  30. Schmitt C, Perel Y, Harousseau J, et al. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother. 2001;45:1561–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Groll AH, Mickiene D, McEvoy M, et al. Safety, pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002;46:2554–63. An interesting study evaluating safety and efficacy of itraconazole at a dose of 2.5 mg/kg BID for the treatment of OPC in pediatric patients > or =5 years old.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol. 1988;18:263–8.

    Article  CAS  PubMed  Google Scholar 

  33. De Beule K. Itraconazole: pharmacology, clinical experience and future development. Int J Antimicrob Agents. 1996;6:175–81.

    Article  PubMed  Google Scholar 

  34. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32:1310–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Mohr JF, Finkel KW, Rex JH, et al. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother. 2004;48:3151–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. De Repentigny L, Ratelle J, Leclerc J-M, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother. 1998;42:404–8.

    PubMed Central  PubMed  Google Scholar 

  37. Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet. 2006;45:1099–114.

    Article  CAS  PubMed  Google Scholar 

  38. Bentley S, Gupta A, Balfour-Lynn IM. Subtherapeutic itraconazole and voriconazole levels in children with cystic fibrosis. J Cyst Fibros. 2013;12:418–9.

    Article  CAS  PubMed  Google Scholar 

  39. Baietto L, D’Avolio A, Ventimiglia G, et al. Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. Antimicrob Agents Chemother. 2010;54:3408–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother. 1990;26:561–6.

    Article  CAS  PubMed  Google Scholar 

  41. Glasmacher A, Hahn C, Molitor E, et al. Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42:591–600.

    Article  CAS  PubMed  Google Scholar 

  42. Naranjo MS, Trujillo M, Munera MI, et al. Treatment of paracoccidioidomycosis with itraconazole. J Med Vet Mycol. 1990;28:67–76.

    Article  CAS  PubMed  Google Scholar 

  43. Lavrijsen APM, Balmus KJ, Nugteren-Huyning WM, et al. Hepatic injury associated with itraconazole. Lancet. 1990;340:251–2.

    Article  Google Scholar 

  44. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357:1766–7.

    Article  CAS  PubMed  Google Scholar 

  45. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447–54.

    Article  CAS  PubMed  Google Scholar 

  46. Chen J, Song X, Yang P, Wang J. Appearance of anaphylactic shock after long-term intravenous itraconazole treatment. Ann Pharmacother. 2009;43:537–41.

    Article  PubMed  Google Scholar 

  47. Baxter CG, Marshall A, Roberts M, et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother. 2011;66:2136–9.

    Article  CAS  PubMed  Google Scholar 

  48. Foot A, Veys P, Gibson B. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant. 1999;24:1089–93.

    Article  CAS  PubMed  Google Scholar 

  49. Simon A, Besuden M, Vezmar S, et al. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer. 2007;15:213–20.

    Article  PubMed  Google Scholar 

  50. https://www.janssen.com.au/Products/Sporanox. SPORANOX® capsule product information (PDF). Revised: 07 February 2015.

  51. Groll AH, Chiou CC, Walsh TJ. Antifungal drugs: drug interactions with antifungal azole derivatives. In: Aronson JK, van Boxtel CJ, editors. Side effects of drugs, annual 24. Amsterdam: Elsevier Science; 2001. p. 314–29.

    Google Scholar 

  52. Gubbins PO, McConnell SA, Penzak SR. Antifungal agents. In: Piscitelli SC, Rodvold KA, editors. Drug interactions in infectious diseases. Totowa: Humana Press; 2001. p. 185–217.

    Chapter  Google Scholar 

  53. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol. 1993;33:1201–6.

    Article  CAS  PubMed  Google Scholar 

  54. Aanpreung P, Veerakul G. Itraconazole for treatment of oral candidosis in pediatric cancer patients. J Med Assoc Thail. 1997;80:358–62.

    CAS  Google Scholar 

  55. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996;60:54–61.

    Article  CAS  PubMed  Google Scholar 

  56. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neuro-toxicity by itraconazole in the treatment of adult ALL. Ann Hematol. 1995;71:311–2.

    Article  CAS  PubMed  Google Scholar 

  57. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med. 1990;113:327–9.

    Article  CAS  PubMed  Google Scholar 

  58. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82:511–6.

    CAS  PubMed  Google Scholar 

  59. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;56:601–7.

    Article  CAS  PubMed  Google Scholar 

  60. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14:165–74.

    Article  CAS  PubMed  Google Scholar 

  61. Abdel-Rahman SM, Powell DA, Nahata MC. Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis. J Am Acad Dermatol. 1998;38:443–6.

    Article  CAS  PubMed  Google Scholar 

  62. Friedlander SF. The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis. Pediatr Infect Dis J. 1999;18:205–10.

    Article  CAS  PubMed  Google Scholar 

  63. Gupta AK, Nolting S, de Prost Y, et al. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology. 1999;199:248–52.

    Article  CAS  PubMed  Google Scholar 

  64. Stein GE, Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother. 1993;37:89–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Foster KW, Friedlander SF, Panzer H. A randomized controlled trial assessing the efficacy of fluconazole in treatment of pediatric tinea capitis. J Am Acad Dermatol. 2005;53:798–809.

    Article  PubMed  Google Scholar 

  66. Lopez-Gomez S, Del Palacio A, Van Cutsem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol. 1994;33:743–7.

    Article  CAS  PubMed  Google Scholar 

  67. Kakourou T, Uksal U, European Society for Pediatric Dermatology. Guidelines for the management of tinea capitis in children. Pediatr Dermatol. 2010;27:226–8.

    Article  PubMed  Google Scholar 

  68. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis: National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28:291–6.

    Article  CAS  PubMed  Google Scholar 

  69. Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15–21.

    Article  PubMed  Google Scholar 

  70. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.

    Article  PubMed  Google Scholar 

  71. Yuanjie Z, Jianghan C, Nan X, et al. Cryptococcal meningitis in immunocompetent children. Mycoses. 2012;55:168–71.

    PubMed  Google Scholar 

  72. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989;86:791–800.

    Article  CAS  PubMed  Google Scholar 

  73. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7:8–24.

    Article  CAS  PubMed  Google Scholar 

  74. Sharkey PA, Graybill JR, Rinaldi MG, et al. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol. 1990;23:577–86.

    Article  CAS  PubMed  Google Scholar 

  75. Mahamaytakit N, Singalavanija S, Limpongsanurak W, et al. Subcutaneous zygomycosis in children: 2 case reports. J Med Assoc Thail. 2014;97:248–53.

    Google Scholar 

  76. De Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliviera R, et al. Treatment of cutaneous sporotrichosis with itraconazole-study of 645 patients. Clin Infect Dis. 2011;52:200–6.

    Article  Google Scholar 

  77. Nascimento CR, Delanina WFB, Soares CT. Paracoccidioidomycosis: sarcoid-like form in childhood. An Bras Dermatol. 2012;87:486–7.

    Article  PubMed  Google Scholar 

  78. Borges SR, Silva GM, Chambela M, et al. Itraconazole vs. trimethoprim-sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis. Med Mycol. 2014;52:303–10.

    Article  CAS  PubMed  Google Scholar 

  79. Chapman SW, Bradsher Jr RW, Campbell Jr GD, et al. Practice guidelines for the management of patients with blastomycosis: Infectious Diseases Society of America. Clin Infect Dis. 2000;30:679–83.

    Article  CAS  PubMed  Google Scholar 

  80. Dismukes WE, Bradsher RW, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med. 1992;93:489–97.

    Article  CAS  PubMed  Google Scholar 

  81. Negroni R, Palmieri O, Koren F, et al. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis. 1987;9:47–50.

    Article  Google Scholar 

  82. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis: Infectious Diseases Society of America. Clin Infect Dis. 2000;30:688–95.

    Article  CAS  PubMed  Google Scholar 

  83. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med. 1995;98:336–42.

    Article  CAS  PubMed  Google Scholar 

  84. Graybill JR, Stevens DA, Galgiani JN, et al. Itraconazole treatment of coccidioidomycosis. Am J Med. 1990;89:282–90.

    Article  CAS  PubMed  Google Scholar 

  85. Tucker RM, Denning DW, Arathoon EG, et al. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol. 1990;23:593–601.

    Article  CAS  PubMed  Google Scholar 

  86. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990;112:108–12.

    Article  CAS  PubMed  Google Scholar 

  87. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000;133:676–86.

    Article  CAS  PubMed  Google Scholar 

  88. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Itraconazole Neutropenia Study Group. Ann Intern Med. 2001;135:412–22. An interesting study comparing the efficacy and safety of itraconazole with those of amphotericin B as empirical antifungal therapy for neutropenic patients.

    Article  CAS  PubMed  Google Scholar 

  89. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161–89.

    Article  PubMed  Google Scholar 

  90. Kim SY, Lim JS, Kim DH, et al. Candida tropicalis arthritis of the elbow in a patient wit Ewing’s sarcoma that successfully responded to itraconazole. Korean J Pediatr. 2011;9:385–8.

    Article  Google Scholar 

  91. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin Infect Dis. 1999;28:250–5.

    Article  CAS  PubMed  Google Scholar 

  92. Kobayashi R, Suzuki D, Yasuda K, Kobayashi K. Itraconazole for invasive fungal infection with pediatric malignancies. Pediatr Int. 2010;52:707–10.

    Article  CAS  PubMed  Google Scholar 

  93. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527–33.

    Article  CAS  PubMed  Google Scholar 

  94. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21:4615–26.

    Article  CAS  PubMed  Google Scholar 

  95. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:327–40. These are the most updated guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Efi Drogouti, Zoe Dorothea Pana, Athanasios Tragiannidis, Georg Hempel, and Andreas Groll all declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Second Pediatric Department, AHEPA General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Efi Drogouti, Zoe Dorothea Pana & Athanasios Tragiannidis

  2. Institute of Pharmaceutical and Medical Chemistry, Department of Clinical Pharmacy, Westfaelische Wilhelms-University Muenster, Münster, Germany

    Georg Hempel

  3. Infectious Disease Research Program, Department of Pediatric Hematology/Oncology, University Children’s Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. A1, 48149, Muenster, Germany

    Andeas Groll

Authors
  1. Efi Drogouti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zoe Dorothea Pana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Athanasios Tragiannidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georg Hempel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andeas Groll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andeas Groll.

Additional information

This article is part of the Topical Collection on Pediatric Fungal Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Drogouti, E., Pana, Z.D., Tragiannidis, A. et al. Clinical Pharmacology of Itraconazole in Children and Adolescents. Curr Fungal Infect Rep 9, 65–73 (2015). https://doi.org/10.1007/s12281-015-0218-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-015-0218-1

Keywords

Search

Navigation